Skip to main content

. 1990 Aug 11;301(6747):345. doi: 10.1136/bmj.301.6747.345-a

Cushing's syndrome induced by medroxyprogesterone.

P K Merrin ¹, W D Alexander ¹

PMCID: PMC1663616 PMID: 2144198

345

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Nemoto T., Patel J., Rosner D., Dao T. L. Oral medroxyprogesterone in the treatment of metastatic breast cancer. J Surg Oncol. 1986 Aug;32(4):211–213. doi: 10.1002/jso.2930320406. [DOI] [PubMed] [Google Scholar]
Siminoski K., Goss P., Drucker D. J. The Cushing syndrome induced by medroxyprogesterone acetate. Ann Intern Med. 1989 Nov 1;111(9):758–760. doi: 10.7326/0003-4819-111-9-758. [DOI] [PubMed] [Google Scholar]
Van Veelen H., Houwerzijl J., Roding T. J., Tjabbes T., Vermeer R. J., Sleijfer D. T., Pratt J. J., Willemse P. H. Oral high-dose medroxyprogesterone acetate causes adrenal suppression in patients with breast cancer. Eur J Cancer Clin Oncol. 1982 Oct;18(10):1035–1036. doi: 10.1016/0277-5379(82)90253-x. [DOI] [PubMed] [Google Scholar]
van Veelen H., Willemse P. H., Sleijfer D. T., Pratt J. J., Sluiter W. J., Doorenbos H. Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients. Cancer Chemother Pharmacol. 1984;12(2):83–86. doi: 10.1007/BF00254594. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES